Radius Health sets terms for IPO

Comment

Shutterstock photo

Radius Health, a biotech developing treatments to restore bone loss from osteoporosis, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $62 million by offering 6.5 million shares at a price range of $8.50 to $10.50. At the midpoint of the proposed range, Radius Health would command a fully diluted market value of $308 million. Radius Health, which was founded in 2003, plans to list on the NASDAQ under the symbol RDUS. UBS Investment Bank and Leerink Swann are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com